Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 4INTERVENTIONAL

Postpartum Hypertension Study

Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.

Who May Be Eligible (Plain English)

Inclusion criteria - Patients admitted to labor and delivery (L\&D) with blood pressure (BP) in severe range, defined as a systolic ≥160 mm Hg and/or diastolic ≥110 mm Hg - Postpartum, immediately to 6 weeks postpartum - With a prior diagnosis of chronic hypertension (not on medication) or hypertensive disorder of pregnancy Exclusion criteria - They may not have previously had exposure to either study medication within the previous 24-hour period. - Patients with a known atrial-ventricular heart block or moderate to severe bronchial asthma will be excluded, or other contraindication to receiving either study medication Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria * Patients admitted to labor and delivery (L\&D) with blood pressure (BP) in severe range, defined as a systolic ≥160 mm Hg and/or diastolic ≥110 mm Hg * Postpartum, immediately to 6 weeks postpartum * With a prior diagnosis of chronic hypertension (not on medication) or hypertensive disorder of pregnancy Exclusion criteria * They may not have previously had exposure to either study medication within the previous 24-hour period. * Patients with a known atrial-ventricular heart block or moderate to severe bronchial asthma will be excluded, or other contraindication to receiving either study medication

Treatments Being Tested

DRUG

Labetalol

Intravenous labetalol, a short acting ant-hypertensive

DRUG

Nifedipine

Oral nifedipine, a short acting ant-hypertensive

Locations (1)

Columbia University Irving Medical Center
New York, New York, United States